The Genitourinary Pathology Society (GUPS) reviewed recent advances in renal neoplasia, particularly post-2016 World Health Organization (WHO) classification, to provide an update on existing entities, including diagnostic criteria, molecular correlates, and updated nomenclature.
Purpose: Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands are a new class of 18F-labeled PSMA-targeting agents. 18F-rhPSMA-7.3 is a lead compound which is currently under investigation in two multicenter phase III trials for PET-imaging.
Prostate-specific membrane antigen (PSMA) is highly expressed on most prostate cancer (PCa) cells and several PSMA ligands for PET imaging (PSMA-PET) are now available worldwide. 68Ga-PSMA-11 has already received American Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval, and PSMA-PET is currently suggested by several international guidelines to investigate PCa in different […]
We hypothesized that co-targeting AR and cell-cycle with palbociclib (a CDK4/6 inhibitor) would improve outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC). 60 patients with Rb-intact mHSPC were randomized (1:2) to Arm 1: androgen deprivation (AD) or Arm 2: AD+ palbociclib.
Clinical trials have strict eligibility criteria, potentially limiting external validity. However, while often discussed this has seldom been explored, particularly across cancer types and at variable time frames post trial completion.
Signaling pathways that drive bladder cancer (BC) progression may be promising and specific targets for systemic therapy. Here, we investigated the clinical significance and targetability of NOTCH and MAPK signaling for this aggressive malignancy.
The androgen receptor (AR) is important in the development of both experimental and human bladder cancer. However, the role of AR in bladder cancer growth and progression is less clear, with literature indicating that more advanced stage and grade disease are associated with reduced AR expression.
Neoadjuvant cisplatin-based combination chemotherapy improves survival in muscle-invasive bladder cancer. However, response rates and survival remain suboptimal. We evaluated the efficacy, safety, and tolerability of cisplatin plus cabazitaxel.
Alicia Morgans: Hi, my name is Alicia Morgans, and I’m a GU Medical Oncologist and Associate Professor of Medicine at Northwestern University in Chicago in the United States. I’m so excited to have here with me today, two friends and colleagues, Dr. Declan Murphy, who is a Professor of Urology at the Peter MacCallum Hospital […]
Petros Grivas: Hello, I’m Petros Grivas, I’m an Associate Professor at the University of Washington in the Fred Hutchinson Cancer Research Center and an Oncologist at Seattle Cancer Care Alliance. I’m very excited and happy today to host Professor Toni Choueiri. He’s a Professor of Medicine at Harvard Medical School, and he’s the Director of the […]
